Author - Leslie BHA

Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More

Immusoft, a California-based cell therapy innovator, is presenting the world’s first clinical trial data for engineered B cells targeting mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by a deficiency in the enzyme iduronidase. This condition triggers a harmful buildup of substances, leading to severe developmental and physical challenges. At ASGCT 2025, Paul J. Orchard, MD, from the University of Minnesota, will share results from a first-in-human trial, highlighting the safety and early efficacy of autologous B cells...
Read more...

KIOXIA and Wasabi Collaborate to Deliver Fast, Intelligent Cloud Object Storage Solution

SAN JOSE, Calif.--(BUSINESS WIRE)--KIOXIA America, Inc. today announced a collaboration with Wasabi Technologies to enhance the speed, reliability, and cost-efficiency of their cloud object storage offering. Since 2022, KIOXIA has worked closely with Wasabi to provide SAS and NVMeTM SSDs for highly performant cloud storage services. As part of this ongoing collaboration, Wasabi is utilizing high-performance enterprise and data center-class NVMe SSDs from KIOXIA for its Hot Cloud Storage Service. Read More>>
Read more...

If student loan domino falls, what’s next for fintechs in the sector?

As of last week, following policy changes under the Trump Administration, borrowers may see hits to their credit scores, wages garnished, tax refunds seized, and reductions in social security benefits. To make sense of how these changes may affect student loan-focused fintechs, as well as their impact on the debt and financial health of US consumers, we interviewed Laurel Taylor, Founder and CEO of NYC-based student debt and savings optimization platform Candidly. Read More>>
Read more...

Elizabeth Banks And Archer Roose’s Next Act: A New Pinot Noir And Doubling Growth

Archer Roose Wines, co-owned by actress Elizabeth Banks, says the canned wine brand is coming off a record year in 2024. What’s next is a new canned pinot noir, the company’s first new red varietal in five years. Co-founder and CEO Marian Leitner-Waldman tells me during a virtual interview that sales volume for Archer Roose Wines exceeded 100,000 nine-liter cases in 2024, a record for the brand, and is currently hitting a 125,000 annualized case volume on a trailing 12-month average....
Read more...

CytoAgents Announces Completion of Cohort 1 Dose-escalation Stage of Clinical Phase 1B to Advance Research on Cytokine Release Syndrome

PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, core cohort dose-limiting toxicity observation period in its ongoing Phase 1b/2a clinical trial. Following a review of safety and efficacy data, the Safety Review Committee (SRC) has approved dose-escalation to the next, higher planned dose in Cohort 2. “This milestone marks an important step forward in our mission to deliver a safe, effective therapy...
Read more...

Candidly, Fiducius Partner to Offer Student Debt Repayment Benefits

Candidly has partnered with Fiducius, a provider of financial wellness benefits, to add tools for college savings and private student lending to the Fiducius platform. The new relationship will allow Candidly to grow its solutions for planning and paying for college and, in turn, enable Fiducius to reach new employee populations. With the addition of Candidly’s student loan refinancing marketplace, both firms believe the collaboration will drive more value for Fiducius users adjusting their student debt repayment strategy amid ongoing changes...
Read more...

New Episode of Never a Dull Moment – Z-Pods

A new Never a Dull Moment episode has dropped! 🎙️ Our host Ziad Henry Moukheiber sits down with Scott Pancoast CEO and founder of Zylö Therapeutics to discuss Z-Pods and more! Press play to hear about Scott's incredible journey from venture capital to starting a business in biotech and cosmetics. Listen to the full episode here.
Read more...

New Episode of Never a Dull Moment – The CFO

🎙️ Never a Dull Moment podcast has released a new episode! 🎙️ In this conversation, host Ziad Henry Moukheiber chats with guest Michael Bayer, CFO of one of Boston Harbor Angels portfolio companies Wasabi Technologies. This fascinating discussion is kicked off with Michael's description of a CFO as a storyteller. Tune in to hear more about about how the role of CFO has evolved!
Read more...

Light Within the Black Hole of Concussion Therapeutics

Last September, the Fédération Internationale de Football Association (FIFA) and the World Health Organization launched the “Suspect and Protect” concussion awareness campaign. In the past few years, the U.S. Department of Defense, the National Hockey League, and the National Football League each introduced plans to minimize concussions, including updating their concussion protocols. And large pharmaceutical companies have done…little. For companies active in this space, their slow progress may be more related to investors’ misperceptions of the topic than the science itself....
Read more...

🍾 HAPPY NEW YEAR 2025 🍾 BOSTON HARBOR ANGELS ENTERS ITS 3RD DECADE OF ANGEL INVESTING

A happy new year to all founders, angels, and everyone else that plays a part in this ecosystem. Boston Harbor Angels wishes them a successful 2025 and upcoming decade! Boston Harbor Angels now enters its 3rd decade of angel investing, helping support and fund great founders, entrepreneurs, and companies. Founded in 2004, Boston Harbor Angels has created an interconnected community and ecosystem of investors, founders and mentors. Boston Harbor Angels is dedicated to helping founders weather the tumultuous battle that...
Read more...